ClinicalTrials.gg
Status unknownNCT03697668ArtesynibUpdated Oct 5, 2018

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

A Phase 2 interventional study of Imatinib and Dihydroartemisinin-piperaquine in Plasmodium Falciparum Malaria (Drug Resistant), sponsored by Nurex S.r.l.. Status unknown at 1 site in Vietnam. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-10-05.

Sponsored by Nurex S.r.l. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2017, registered Jul 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Malaria, Falciparum with a site in Vietnam — none open to participants now, none under way, none of them phase 3. Malaria, Falciparum · Vietnam.

Planned enrollment
9th of 10
50 · median 486
Started
2017
with 1 other
Phase 2
2 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Nurex S.r.l.

Among the 11 studies in Malaria, Falciparum with a site in Vietnam, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 11th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

None of the 11 studies in Malaria, Falciparum with a site in Vietnam is open now. The open studies under Malaria, Falciparum, anywhere →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Malaria, Falciparum with a site in Vietnam as a file.
02

Study summary

The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.

Read the detailed description

According to WHO, resistance to artemisinin derivatives (ART) is emerging in many areas of the Greater Mekong Region as a delayed parasite clearance following a standard treatment by artemisinin combined therapy (ACT). Artemisinin resistance is often accompanied by the resistance to the partner drugs such as piperaquine (PPQ), mefloquine (MEF), amodiaquine (AQ) and lumefantrine (LF).

The slow and incomplete clearance of parasites following ACT treatment is considered to permit the selection of resistant parasites.

The availability of new, more efficient treatments accelerating the clearance of parasites is therefore needed to counteract the selection of ART resistant strains.

Imatinib (IMA) has been demonstrated to increase the efficacy of ART in a synergic fashion. This positive effect is further potentiated by low concentrations of PPQ.

IMA is active both on the intra-erythrocyte asexual forms and on gametocytes. It is therefore expected that the combination DHA-PPQ-IMA should lead to faster and radical clearance of the parasites, therefore reducing the frequency of healthy carriers and transmission.

03

Conditions studied

  • Plasmodium Falciparum Malaria (Drug Resistant)

Browse trials for

Keywords

  • Imatinib Mesylate
  • piperaquine phosphate
  • dihydroartemisinin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with mild to moderate P. falciparum malaria
  2. Adult male, age 18-55 years
  3. Good health conditions other than malaria
  4. The patient did not take anti-malarial drugs in the past 4 weeks

Exclusion criteria

Exclusion Criteria:

  1. unable to provide or Patient History Form
  2. symptoms and signs of severe or complicated malaria including: continuous high fever over 39 °C, confusion, convulsions
  3. parasitemia\<150.000 parasites /microliter
  4. other neurological or psychiatric symptoms or disorders
  5. abnormal bleeding
  6. resting hearth rate lower than 60 and higher than 100 bpm
  7. abnormal , history of cardiac diseases
  8. male adults with intervals > 450ms
  9. signs, symptoms and laboratory results of impairment of vital organs such as liver, lungs, kidney and cardiovascular system
  10. \< 9.0 gm/100ml
  11. symptoms and signs of infection such as pneumonia, dengue fever, and other viral or bacterial infection.
  12. patients with symptoms of gastrointestinal infections or any sign of malabsorption that may interfere with drug absorption
  13. concomitant infection by plasmodium species other than P. falciparum
  14. inability to meet daily with local doctor during period of clinical trial
  15. concomitant medicines like:

    1. medicines used to treat high cholesterol in the blood (such as atorvastatin, lovastatin, simvastatin);
    2. medicines used to treat hypertension and heart problems (such as diltiazem, nifedipine, nitrendipine, verapamil, felodipine, amlodipine);
    3. medicined used to treat (antiretroviral medicines): protease inhibitors (such as amprenavir, atazanavir, indinavir, nelfinavir, ritonavir), non-nucleoside reverse transcriptase inhibitors (such as efavirenz, nevirapine);
    4. medicines used to treat microbial infections (such as telithromycin, rifampicin, dapsone);
    5. medicines used to help you fall asleep: benzodiazepines (such as midazolam, triazolam, diazepam, alprazolam), zaleplon, zolpidem;
    6. medicines used to prevent/treat epileptic seizures: barbiturates (such as phenobarbital), carbamazepine or phenytoin;
    7. medicines used after organ transplantation and in diseases (such as cyclosporin, tacrolimus);
    8. sex hormones, including those contained in hormonal (such as gestodene, progesterone, estradiol), testosterone; - (hydrocortisone, dexamethasone); - omeprazole (used to treat diseases related to gastric acid production);
    9. paracetamol (used to treat pain and fever);
    10. theophylline (used to improve bronchial air flow);
    11. nefazodone (used to treat depression);
    12. aprepitant (used to treat nausea);
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    imatinib-Dihydroartemisinin-piperaquine

    triple combination

    Drug: Imatinib

  • Active comparator
    Dihydroartemisinin-piperaquine

    standard of care

    Drug: Dihydroartemisinin-piperaquine

Interventions

  • triple combination for the treatment of malaria

    Also known as: Gleevec, Glivec

  • DrugDihydroartemisinin-piperaquine

    Drug pages: Artenimol · Piperaquine

    standard malaria treatment

    Also known as: Artekin, Eurartesim, Diphos, Timequin, Duocotecxin

06

What researchers measure

Primary outcomes

  1. Occurrence of Adverse Events

    Occurrence of Adverse Events over 42 days observation period

    Time frame: From baseline to day 42

  2. Occurrence of Severe Adverse Events

    Occurrence of Severe Adverse Events over 42 days observation period

    Time frame: From baseline to day 42

  3. Occurrence of Abnormal Physical Symptoms

    Occurrence of Abnormal Physical Symptoms (Clinical Abnormalities) over 42 days observation period

    Time frame: From baseline to day 42

  4. Occurrence of Abnormal Laboratory Values

    Occurrence of Abnormal Laboratory Values over 42 days observation period

    Time frame: From baseline to day 42

Secondary outcomes

  1. Frequency of residual parasitemia: % of patients with >1000 parasites/ ul at day 3 and 28

    Parasitemia is determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis.

    Time frame: day 3 and day 28

  2. Frequency of fever and malaria symptoms

    Percentage of patients with fever or malaria symptoms observed at Phisical Visit at day 3 and 28.

    Time frame: day 3 and day 28

  3. Mean parasitemia in the control and investigational arms

    Mean parasitemia by assessing the parasite count in blood, using thin film, thick film and qPCR analysis, expressed as parasites / ul at day 2, 3 and 5 measured in the control and investigational arms

    Time frame: day 2 and day 5

  4. Parasite half-life measured at 12 and 24 hours

    Mean parasite clearance half-life calculated using parasitemia measured at baseline, 12 and 24 hours post-treatment

    Time frame: from baseline to 24 hours post-treatment

07

Study locations

1 of 1 sites recruiting
  • A Tuc
    Hương Hóa, Quang Tri 520000, Vietnam
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2018, 15 months after the start.

Of 39 phase 2 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's planned 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2018
First posted
Oct 5, 2018
StartActual
Sep 17, 2017
Primary completionEst.
Dec 31, 2018
CompletionEst.
Dec 31, 2019
Last update
Oct 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03697668
Lead sponsor
Nurex S.r.l.
Collaborators
Università degli Studi di Sassari, Purdue University, Vinmec Healthcare System
Responsible party
Sponsor
First posted
Oct 5, 2018
Start date
Sep 17, 2017
Primary completion
Dec 31, 2018 (estimated)
Completion
Dec 31, 2019 (estimated)
Last update
Oct 5, 2018

Study contacts

Huynh D Chien, MD,PhD
Contact
huynhdinhchien55@gmail.com
+84903580518
Tran A Tuan, MD
Contact
tuanhuonghoa@gmail.com
+84982290426
Huynh D Chien, MD, PhD
principal investigator · UNIVERSITY OF HUE, VIETNAM AND VINMEC DANANG INTERNATIONAL HOSPITAL, Hai Chau, Danang.
Francesco M Turrini, MD, PhD
principal investigator · University of Turin, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion